DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Up 72.5% in August

Key Points

• Short interest in DBV Technologies S.A. (NASDAQ:DBVT) increased by 72.5% in August, reaching a total of 18,800 shares by August 31st.
• Several hedge funds and institutional investors have newly acquired stakes in DBV Technologies, with a combined investment of around $9.6 million from multiple firms in the 2nd quarter.
• The company's latest earnings report showed a loss of ($1.55) per share, significantly missing analyst expectations, although it achieved revenues of $1.74 million for the quarter.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 18,800 shares, an increase of 72.5% from the August 15th total of 10,900 shares. Based on an average daily trading volume, of 29,800 shares, the short-interest ratio is presently 0.6 days. Approximately 0.1% of the shares of the stock are short sold. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 29,800 shares, the short-interest ratio is presently 0.6 days.

Hedge Funds Weigh In On DBV Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in DBVT. Vivo Capital LLC bought a new position in shares of DBV Technologies during the 2nd quarter worth about $9,659,000. Adage Capital Partners GP L.L.C. acquired a new stake in DBV Technologies in the 2nd quarter valued at about $9,659,000. MPM Bioimpact LLC acquired a new stake in DBV Technologies in the 2nd quarter valued at about $9,649,000. Octagon Capital Advisors LP acquired a new stake in DBV Technologies in the 2nd quarter valued at about $9,315,000. Finally, Nan Fung Trinity HK Ltd. acquired a new stake in DBV Technologies in the 2nd quarter valued at about $340,000. 71.74% of the stock is owned by institutional investors.

DBV Technologies Trading Up 0.3%

Shares of NASDAQ DBVT traded up $0.03 during midday trading on Monday, reaching $9.90. The company's stock had a trading volume of 72,334 shares, compared to its average volume of 187,738. DBV Technologies has a one year low of $2.20 and a one year high of $12.78. The company has a 50 day moving average price of $9.71 and a 200 day moving average price of $8.59. The company has a market cap of $271.21 million, a price-to-earnings ratio of -2.08 and a beta of -0.36.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.34). The firm had revenue of $1.74 million for the quarter, compared to analyst estimates of $0.64 million. DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. Research analysts anticipate that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on DBVT. Wall Street Zen lowered shares of DBV Technologies from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. The Goldman Sachs Group raised shares of DBV Technologies to a "sell" rating and set a $7.25 target price on the stock in a report on Thursday, May 29th. Lifesci Capital raised shares of DBV Technologies to a "strong-buy" rating in a report on Thursday, June 26th. JMP Securities reissued a "market outperform" rating and set a $21.00 price objective on shares of DBV Technologies in a research note on Thursday, June 26th. Finally, Citigroup reissued an "outperform" rating on shares of DBV Technologies in a research report on Tuesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, DBV Technologies has a consensus rating of "Moderate Buy" and an average target price of $14.75.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.